Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVAC MUTANOME in Advanced Melanoma
NCT02035956Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Dec 2013
- Primary completion
- Feb 2017
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of BNT121 in melanoma, sponsored by BioNTech SE. Primary endpoint: Safety and tolerability of repetitive doses at 189 days. Started Dec 2013; status: completed.
02
Drugs
BNT121
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02035956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035956.